SEARCH

SEARCH BY CITATION

References

  • 1
    Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 126778.
  • 2
    Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 10019.
  • 3
    Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 161522.
  • 4
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13839.
  • 5
    LI PID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 134957.
  • 6
    Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 6217.
  • 7
    Hori A, Kanda Y, Goyama S et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005; 79: 3724.
  • 8
    Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 585661.
  • 9
    Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 68792.
  • 10
    Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399402.
  • 11
    Romano M, Diomede L, Sironi M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095100.
  • 12
    Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. Lyon: IARC Scientific Publications 2003.
  • 13
    Devesa SS, Fears T. Non-Hodgkins-lymphoma time trends − United States and international data. Cancer Res 1992; 52: S543240.
  • 14
    Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 1999; 83: 4815.
  • 15
    Opelz G, Schwarz V, Henderson R, Kneifel G, Ruhenstroth A. Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. Transpl Int 1994; 7 (Suppl. 1): S3536.
  • 16
    Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 36339.
  • 17
    Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 18999.
  • 18
    Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 6205.
  • 19
    Iwata H, Matsuo K, Takeuchi K, Kishi Y, Murashige N, Kami M. High incidences of malignant lymphoma in patients infected with hepatitis B or hepatitis C virus. Haematologica 2004; 89: 36870.
  • 20
    Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004; 95: 74552.
  • 21
    Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 5560.
  • 22
    Jacobs D, Blackburn H, Higgins M et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 104660.
  • 23
    Kritchevsky SB. Dietary lipids and the low blood cholesterol–cancer association. Am J Epidemiol 1992; 135: 50920.
  • 24
    Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 71623.
  • 25
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 31321.
  • 26
    Iwata H, Aoyama T, Kusumi E, Hamaki T, Kami M. Limitations of a meta-analysis investigating the association between cancer and statin use. Am J Med 2002; 112: 1578.
  • 27
    Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer 2002; 86: 14369.
  • 28
    Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: 31825.
  • 29
    Friis S, Poulsen AH, Johnsen SP et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 6437.
  • 30
    Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 218492.
  • 31
    Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13: 2627.
  • 32
    Franceschi S, Serraino D, Carbone A, Talamini R, La Vecchia C. Dietary factors and non-Hodgkin's lymphoma: a case-control study in the northeastern part of Italy. Nutr Cancer 1989; 12: 33341.
  • 33
    Matsuo K, Hamajima N, Hirose K et al. Alcohol, smoking, and dietary status and susceptibility to malignant lymphoma in Japan: results of a hospital-based case-control study at Aichi Cancer Center. Jpn J Cancer Res 2001; 92: 101117.
  • 34
    Matsuo K, Suzuki R, Hamajima N et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001; 97: 32059.
  • 35
    Kersey JH, Shapiro RS, Filipovich AH. Relationship of immunodeficiency to lymphoid malignancy. Pediatr Infect Dis J 1988; 7: S1012.
  • 36
    Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 38692.
  • 37
    Cote TR, Biggar RJ, Rosenberg PS et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73: 64550.
  • 38
    Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 53740.
  • 39
    Cohen JI. Epstein–Barr virus infection. N Engl J Med 2000; 343: 48192.
  • 40
    Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 50819.
  • 41
    Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 73945.